Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRACLE: Pirtobrutinib and Venetoclax in Previously Untreated CLL/SLL
NCT05677919Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib, venetoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Mayo Clinic. Started Jan 2023; status: active, not recruiting.
02
Drugs
pirtobrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05677919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677919.